BDFS Capital LLC Buys Shares of 992 IDEXX Laboratories, Inc. $IDXX

Posted by on Jun 19th, 2026

BDFS Capital LLC purchased a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 992 shares of the company’s stock, valued at approximately $671,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Elyxium Wealth LLC bought a new stake in IDEXX Laboratories during the fourth quarter worth approximately $3,666,459,000. State Street Corp grew its position in IDEXX Laboratories by 4.0% during the 4th quarter. State Street Corp now owns 3,656,626 shares of the company’s stock worth $2,473,817,000 after purchasing an additional 138,956 shares during the last quarter. J. Stern & Co. LLP lifted its stake in shares of IDEXX Laboratories by 23,694.7% during the fourth quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock worth $1,795,072,000 after buying an additional 2,642,200 shares during the period. Geode Capital Management LLC lifted its position in IDEXX Laboratories by 3.5% during the 4th quarter. Geode Capital Management LLC now owns 2,583,939 shares of the company’s stock worth $1,749,380,000 after acquiring an additional 86,263 shares during the period. Finally, Invesco Ltd. lifted its holdings in shares of IDEXX Laboratories by 13.8% during the fourth quarter. Invesco Ltd. now owns 1,502,218 shares of the company’s stock worth $1,016,296,000 after purchasing an additional 181,955 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $562.09 on Friday. The stock’s 50-day moving average is $562.26 and its two-hundred day moving average is $621.32. The firm has a market cap of $44.34 billion, a price-to-earnings ratio of 41.39, a PEG ratio of 2.99 and a beta of 1.55. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. IDEXX Laboratories, Inc. has a 1 year low of $506.91 and a 1 year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. The company had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. IDEXX Laboratories’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period in the previous year, the business posted $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Analysts predict that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

Wall Street Analysts Forecast Growth

IDXX has been the topic of several recent research reports. Stifel Nicolaus lowered their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Wall Street Zen raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, June 13th. UBS Group reduced their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Finally, Citigroup initiated coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price on the stock. Seven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus price target of $751.00.

Check Out Our Latest Stock Analysis on IDXX

IDEXX Laboratories Profile

(Free Report)

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

See Also

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.